As of 2025-01-25, the EV/EBITDA ratio of ANI Pharmaceuticals Inc (ANIP) is -29.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ANIP's latest enterprise value is 1,712.99 mil USD. ANIP's TTM EBITDA according to its financial statements is -58.52 mil USD. Dividing these 2 quantities gives us the above ANIP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 9.0x | 8.6x |
| Forward P/E multiples | 7.9x - 9.7x | 8.8x |
| Fair Price | (45.74) - 8.19 | (20.70) |
| Upside | -178.0% - -86.0% | -135.3% |
| Date | EV/EBITDA |
| 2025-01-15 | -28.52 |
| 2025-01-14 | -27.66 |
| 2025-01-13 | -27.58 |
| 2025-01-10 | -27.98 |
| 2025-01-08 | -27.66 |
| 2025-01-07 | -27.74 |
| 2025-01-06 | -27.82 |
| 2025-01-03 | -28.14 |
| 2025-01-02 | -28.12 |
| 2024-12-31 | -28.06 |
| 2024-12-30 | -27.68 |
| 2024-12-27 | -27.75 |
| 2024-12-26 | -28.14 |
| 2024-12-24 | -27.66 |
| 2024-12-23 | -27.68 |
| 2024-12-20 | -27.37 |
| 2024-12-19 | -27.70 |
| 2024-12-18 | -27.56 |
| 2024-12-17 | -28.26 |
| 2024-12-16 | -28.45 |
| 2024-12-13 | -28.53 |
| 2024-12-12 | -28.52 |
| 2024-12-11 | -29.46 |
| 2024-12-10 | -29.46 |
| 2024-12-09 | -29.05 |
| 2024-12-06 | -28.67 |
| 2024-12-05 | -28.32 |
| 2024-12-04 | -28.63 |
| 2024-12-03 | -28.64 |
| 2024-12-02 | -28.99 |
| 2024-11-29 | -28.76 |
| 2024-11-27 | -29.54 |
| 2024-11-26 | -28.99 |
| 2024-11-25 | -29.27 |
| 2024-11-22 | -28.65 |
| 2024-11-21 | -28.27 |
| 2024-11-20 | -28.00 |
| 2024-11-19 | -28.21 |
| 2024-11-18 | -28.05 |
| 2024-11-15 | -28.53 |
| 2024-11-14 | -29.37 |
| 2024-11-13 | -29.70 |
| 2024-11-12 | -30.12 |
| 2024-11-11 | -30.38 |
| 2024-11-08 | -30.28 |
| 2024-11-07 | -29.18 |
| 2024-11-06 | -29.18 |
| 2024-11-05 | -28.79 |
| 2024-11-04 | -28.33 |
| 2024-11-01 | -29.11 |